The Latest
-
Getty Images
Q&AMapLight CEO on what investors missed in the biotech’s schizophrenia data
Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Apnimed raised $192 million in the biopharmaceutical sector’s 15th IPO this year, while a trio of other drugmakers — Braveheart Bio, Attovia Therapeutics and Vogenx — set terms for coming offerings.
Updated July 31, 2026 -
Getty Images
Emerging biotechJ&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
-
Getty Images
Capricor Duchenne cell therapy voted down by FDA panel
At a contentious meeting with possible implications for other rare disease drugmakers, outside experts ultimately determined that Capricor didn't prove deramiocel's benefits in Duchenne-related cardiomyopathy.
-
Alamy
Trump administration5 FDA decisions to watch in the third quarter of 2026
A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.
-
Courtesy of Hims & Hers
FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices
Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”
-
Getty Images
Emerging biotechCaldera, Vidya add to recent flurry of biotech mergers
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.
-
Alamy
The FDA was all in on AI. Will that change?
High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.
-
Getty Images
GSK prepares for patent cliff with $2.5B cost-cutting plan
The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.
-
Getty Images
News roundupFDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.
-
Permission granted by Vertex Pharmaceuticals
AbCellera, Vertex partner on next-gen T-cell engagers
The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.
-
Getty Images
Emerging biotechAn eye drug biotech banks $118M and stocks its executive suite
Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.
-
Jacob Bell/BioPharma Dive
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.
-
Getty Images
News roundup
FDA scientists question Capricor data; Legend CEO steps down
Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.
-
Getty Images
Brain drug revivalMapLight dives despite positive data for schizophrenia drug
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
-
Sarah Silbiger via Getty Images
Trump administrationFDA panel endorses broader use of certain peptides
In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven peptides up for consideration despite a lack of substantive evidence supporting their benefits and safety.
Updated July 26, 2026 -
Getty Images
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.
-
Courtesy of Sanofi
Sanofi halts development of troubled immune drug in eczema
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.
-
Getty Images
IPO windowScribe secures $129M in a rare gene editing IPO
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.
-
Scott Olson via Getty Images
Obesity drugsLilly, with new data, to seek FDA approval of obesity drug retatrutide
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
Argenx is paying $2.2 billion to acquire Forte Biosciences, the developer of a CD122-targeting antibody drug that’s shown early promise against multiple immunological conditions.
Updated July 27, 2026 -
Permission granted by Vertex Pharmaceuticals
Vertex was sole bidder in high-premium Crinetics acquisition
Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.
-
Getty Images
News roundup
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
-
Courtesy of GSK
GSK lung cancer drug gets speedy approval following $10.6B deal
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
-
Getty Images
Obesity drugsNovo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”
